Physician profile
Christopher Greb
NPI 1134623895
$1,394.07
in general payments reported to CMS, 2019-2025
9 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $183 · 2024: $848 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,394.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $471.31 | 2023-2024 | Tezspire, Airsupra |
| Genzyme Corporation | $261.63 | 2023-2024 | |
| Biocryst US Sales Co., LLC | $150.00 | 2025 | Orladeyo |
| Blueprint Medicines Corporation | $112.02 | 2024 | Ayvakit |
| Glaxosmithkline, LLC. | $109.03 | 2025 | Nucala |
| Ars Pharmaceuticals Operations, INC. | $103.45 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $87.22 | 2024 | |
| Kedrion Biopharma, INC. | $80.14 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Collegium Pharmaceutical, INC. | $19.27 | 2024 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Greb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.